Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $18.34 billion. The enterprise value is $15.11 billion.
| Market Cap | 18.34B |
| Enterprise Value | 15.11B |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.57 million shares outstanding. The number of shares has decreased by -3.12% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.57M |
| Shares Change (YoY) | -3.12% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 52.82% |
| Float | 60.85M |
Valuation Ratios
The trailing PE ratio is 11.59 and the forward PE ratio is 15.58.
| PE Ratio | 11.59 |
| Forward PE | 15.58 |
| PS Ratio | 4.77 |
| Forward PS | 4.27 |
| PB Ratio | 3.19 |
| P/TBV Ratio | 5.03 |
| P/FCF Ratio | 13.81 |
| P/OCF Ratio | 13.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.31, with an EV/FCF ratio of 11.38.
| EV / Earnings | 9.55 |
| EV / Sales | 3.93 |
| EV / EBITDA | 10.31 |
| EV / EBIT | 10.66 |
| EV / FCF | 11.38 |
Financial Position
The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.03 |
| Quick Ratio | 6.01 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.11 |
| Interest Coverage | 54.85 |
Financial Efficiency
Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 16.02%.
| Return on Equity (ROE) | 29.41% |
| Return on Assets (ROA) | 13.38% |
| Return on Invested Capital (ROIC) | 16.02% |
| Return on Capital Employed (ROCE) | 22.58% |
| Revenue Per Employee | $1.43M |
| Profits Per Employee | $590,331 |
| Employee Count | 2,682 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 17.23 |
Taxes
In the past 12 months, Genmab has paid $196.37 million in taxes.
| Income Tax | 196.37M |
| Effective Tax Rate | 11.03% |
Stock Price Statistics
The stock price has increased by +31.33% in the last 52 weeks. The beta is 0.79, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +31.33% |
| 50-Day Moving Average | 29.78 |
| 200-Day Moving Average | 23.35 |
| Relative Strength Index (RSI) | 56.15 |
| Average Volume (20 Days) | 2,563,759 |
Short Selling Information
The latest short interest is 6.68 million, so 1.10% of the outstanding shares have been sold short.
| Short Interest | 6.68M |
| Short Previous Month | 5.56M |
| Short % of Shares Out | 1.10% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.80 |
Income Statement
In the last 12 months, Genmab had revenue of $3.85 billion and earned $1.58 billion in profits. Earnings per share was $25.10.
| Revenue | 3.85B |
| Gross Profit | 3.63B |
| Operating Income | 1.42B |
| Pretax Income | 1.78B |
| Net Income | 1.58B |
| EBITDA | 1.47B |
| EBIT | 1.42B |
| Earnings Per Share (EPS) | $25.10 |
Balance Sheet
The company has $3.41 billion in cash and $142.00 million in debt, giving a net cash position of $3.27 billion or $53.10 per share.
| Cash & Cash Equivalents | 3.41B |
| Total Debt | 142.00M |
| Net Cash | 3.27B |
| Net Cash Per Share | $53.10 |
| Equity (Book Value) | 5.75B |
| Book Value Per Share | 93.41 |
| Working Capital | 3.73B |
Cash Flow
In the last 12 months, operating cash flow was $1.37 billion and capital expenditures -$40.38 million, giving a free cash flow of $1.33 billion.
| Operating Cash Flow | 1.37B |
| Capital Expenditures | -40.38M |
| Free Cash Flow | 1.33B |
| FCF Per Share | $21.58 |
Margins
Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.
| Gross Margin | 94.36% |
| Operating Margin | 36.87% |
| Pretax Margin | 46.28% |
| Profit Margin | 41.17% |
| EBITDA Margin | 38.12% |
| EBIT Margin | 36.87% |
| FCF Margin | 34.54% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.12% |
| Shareholder Yield | 3.12% |
| Earnings Yield | 8.63% |
| FCF Yield | 7.24% |
Analyst Forecast
The average price target for Genmab is $40.40, which is 33.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.40 |
| Price Target Difference | 33.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 15.09% |
| EPS Growth Forecast (5Y) | 10.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.17 |
| Piotroski F-Score | 5 |